home All News open_in_new Full Article

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a […]


today 8 d. ago attach_file Sport

attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Culture
attach_file Events
attach_file Politics
attach_file Culture
attach_file Economics
attach_file Politics
attach_file Other
attach_file Politics
attach_file Other
attach_file Other
attach_file Sport
attach_file Events
attach_file Science
attach_file Economics
attach_file Economics
attach_file Other


ID: 4275151115
Add Watch Country

arrow_drop_down